Overview

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Status:
Completed
Trial end date:
2016-01-28
Target enrollment:
Participant gender:
Summary
This is a biomedical and prospective study of interventional type. The trial will include 29 patients over a period of 15 months + 24 months of follow up maximum. The study will be conduct in womens with metastatic invasive breast cancer or locally advanced breast cancer and for which treatment with tamoxifen or anti aromatase (first line hormone therapy for metastatic breast cancer) is indicated. The main objective of this pilot study is to evaluate the feasibility to detect in the circulating blood of patients, before treatment (T0), the presence of the fifteen tissular microRNAs described in preclinical studies as possibly involved in hormone resistance/sensitivity. In parallel of the detection of these specific miRNAs, we will conduct a larger scale analysis of circulating miRNAs in these patients before (T = 0) and after one month of treatment (T28).
Phase:
Phase 4
Details
Lead Sponsor:
Institut Claudius Regaud
Treatments:
Anastrozole
Exemestane
Hormones
Letrozole
Tamoxifen